ArticleBMC cancer2025
Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTertiary lymphoid structures (TLSs), ectopic lymphoid aggregates composed of immune cells, are associated with favorable clinical outcomes and increased efficacy of anti-tumor immunotherapies. However, the mechanisms underlying the formation and maturation of TLSs require further elucidation. The correlation between tumor immune microenvironment in tumor-draining lymph nodes (TDLNs) and TLSs remains inadequately studied. The study aimed to utilize multiplex immunofluorescence (mIF) to explore the relationship between TDLN and TLSs.
methodsTissue slides from 120 patients with lung adenocarcinoma (LUAD) were collected to perform for mIF staining. Panel 1 (DAPI, CD20, CD21, CD23) was used for the quantitative and qualitative analyses of TLS. Panel 2 (DAPI, CD4, CD8, CD20) was used to describe the immune microenvironment of the tumor and TDLN.
resultsTLS (+) patients showed better disease-free survival (DFS) (mDFS, 70.8 vs. 28.7 months; p = 0.013, HR = 0.555, 95% CI 0.352 to 0.875) and overall survival (OS) (mOS, 77.83 months vs. not reached; p = 0.028, HR = 0.512, 95% CI 0.289 to 0.907) compared to TLS (-) patients. B cells in the tumor and TDLN determined the formation of TLSs. A higher percentage of B cells in the tumor / B cells in the TDLN correlated with a higher number of TLSs (p < 0.0001, r = 0.349). In addition, a high percentage of TIM-1 + B cells /B cells in the TDLN was correlated with a reduced percentage of mature TLSs (p < 0.001, r=-0.441).
conclusionThis study demonstrated that B cells in the tumor and TDLN play critical roles in the formation and maturation of TLS. TIM-1 + B cell is a unique immunosuppressive B cell subset that impedes the maturation of TLS and could be a promising target for improving the maturation of TLS and the prognosis of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.